

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis

Jeffrey A Cohen, Peter B Imrey, Sarah M Planchon, Robert A Bermel, Elizabeth Fisher, Robert J Fox, Amit Bar-Or, Susan L Sharp, Thomai T Skaramagas, Patricia Jagodnik, Matt Karafa, Shannon Morrison, Jane Reese Koc, Stanton L Gerson and Hillard M Lazarus

Abstract

Background: Mesenchymal stem cells (MSCs) exhibit immunomodulatory, tissue-protective, and repair-promoting properties in vitro and in animals. Clinical trials in several human conditions support the safety and efficacy of MSC transplantation. Published experience in multiple sclerosis (MS) is modest.

Objective: To assess feasibility, safety, and tolerability and explore efficacy of autologous MSC transplantation in MS.

Methods: Participants with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS), Expanded Disability Status Scale score 3.0–6.5, disease activity or progression in the prior 2 years, and optic nerve involvement were enrolled. Bone-marrow-derived MSCs were culture-expanded and then cryopreserved. After confirming fulfillment of release criteria, $1\text{--}2 \times 10^6$ MSCs/kg were thawed and administered IV.

Results: In all, 24 of 26 screened patients were infused: 16 women and 8 men, 10 RRMS and 14 SPMS, mean age 46.5, mean Expanded Disability Status Scale score 5.2, 25% with gadolinium-enhancing magnetic resonance imaging (MRI) lesions. Mean cell dosage (requiring 1–3 passages) was 1.9×10^6 MSCs/kg (range, 1.5–2.0) with post-thaw viability uniformly $\geq 95\%$. Cell infusion was tolerated well without treatment-related severe or serious adverse events, or evidence of disease activation.

Conclusion: Autologous MSC transplantation in MS appears feasible, safe, and well tolerated. Future trials to assess efficacy more definitively are warranted.

Keywords: Multiple sclerosis, clinical trial, mesenchymal stem cells, safety, disability measures, quantitative MRI

Date received: 10 February 2017; revised: 13 March 2017; accepted: 17 March 2017

Introduction

Multiple sclerosis (MS) pathology is characterized by multifocal central nervous system lesions with perivascular inflammatory cell infiltrates, demyelination, axonal transection, neuronal degeneration, and gliosis. Currently approved therapies are effective in relapsing MS, where they prevent accumulation of focal inflammatory damage, but none has been shown to directly promote repair.

Mesenchymal stem cells (MSCs), also known as multipotent stromal cells, can be isolated from multiple adult tissues including bone marrow, culture-expanded ex vivo, and induced to differentiate into cells of the

mesodermal lineage, including osteoblasts, adipocytes, and chondrocytes. Their pleotropic immunomodulatory and repair-promoting effects and ability to traffic to areas of tissue inflammation and damage have led to testing in various inflammatory and tissue injury conditions and also make them attractive as a potential treatment for MS.¹ Pilot studies utilizing cells from several sources and tested in a variety of clinical settings have supported their safety and potential efficacy.¹ An uncontrolled phase 1/2 study in secondary progressive multiple sclerosis (SPMS) suggested tissue repair within the afferent visual system.² A recent small randomized phase 2 crossover study in relapsing-remitting multiple sclerosis (RRMS) suggested reduced

Multiple Sclerosis Journal

2018, Vol. 24(4) 501–511

DOI: 10.1177/
1352458517703802

© The Author(s), 2017.
Reprints and permissions:
[http://www.sagepub.co.uk/
journalsPermissions.nav](http://www.sagepub.co.uk/journalsPermissions.nav)

Correspondence to:
JA Cohen
Mellen Center for MS
Treatment and Research,
Neurological Institute,
Cleveland Clinic, 9500
Euclid Avenue, Cleveland,
OH 44195, USA.
cohenj@ccf.org

Jeffrey A Cohen
Sarah M Planchon
Robert A Bermel
Robert J Fox
Susan L Sharp
Thomai T Skaramagas
Mellen Center for MS
Treatment and Research,
Neurological Institute,
Cleveland Clinic, Cleveland,
OH, USA

Matt Karafa
Shannon Morrison
Department of Quantitative
Health Sciences, Lerner
Research Institute, Cleveland
Clinic, Cleveland, OH, USA

Patricia Jagodnik
Department of Biomedical
Engineering, Lerner Research
Institute, Cleveland Clinic,
Cleveland, OH, USA

Jane Reese Koc
Stanton L Gerson
Hillard M Lazarus
Case Comprehensive Cancer
Center and National Center
for Regenerative Medicine,
Case Western Reserve
University and Seidman
Cancer Center, University
Hospitals Cleveland Medical
Center, Cleveland, OH, USA

Peter B Imrey
Mellen Center for MS
Treatment and Research,
Neurological Institute,
Cleveland Clinic, Cleveland,
OH, USA/Department of
Quantitative Health Sciences,
Lerner Research Institute,
Cleveland Clinic, Cleveland,
OH, USA

Elizabeth Fisher
Department of Biomedical
Engineering, Lerner Research
Institute, Cleveland Clinic,
Cleveland, OH, USA/Biogen,
Cambridge, MA, USA

Amit Bar-Or
Montreal Neurological
Institute, McGill University,
Montreal, QC, Canada/
Department of Neurology,
University of Pennsylvania,
Philadelphia, PA, USA

gadolinium-enhancing brain MRI lesions.³ Based on regulatory input on study design, we undertook a phase 1 study of autologous, culture-expanded MSC transplantation in MS, focusing on feasibility, safety, and tolerability.

Materials and methods

Study design

This open-label, phase 1 pre–post comparison study enrolled participants at the Cleveland Clinic Mellen Center for MS Treatment and Research between March 2011 and April 2013. Bone marrow aspiration was performed in the Dahms Clinical Research Unit at University Hospitals Cleveland Medical Center (UHCMC). MSC isolation and culture-expansion were performed in the National Center for Regenerative Medicine Cellular Therapy Laboratory at Case Western Reserve University, as previously described.⁴ The Cleveland Clinic and UHCMC Institutional Review Boards approved the study. Participants gave written consent before any study-related procedures were performed. The study was conducted in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice⁵ and the principles of the Declaration of Helsinki.⁶ A Steering Committee designed the study and monitored its conduct. A Medical Monitor and independent Data and Safety Monitoring Committee reviewed trial conduct and safety data. Additional administrative details are available in the Supplementary Appendix.

Participants

Eligible participants were 18–55 years of age and had RRMS or SPMS fulfilling the 2010 McDonald Criteria;⁷ Expanded Disability Status Scale (EDSS) score 3.0–6.5;⁸ documented relapse, worsening disability, or MRI lesion activity in the prior 2 years; evidence of optic nerve involvement clinically, on visual evoked potentials (VEP), or optic coherence tomography (OCT); and brain MRI demonstrating T2-hyperintense lesions fulfilling MS diagnostic criteria.⁹ Participants could continue interferon-beta or glatiramer acetate, but other disease therapies were discontinued for varying durations prior to screening.

Intervention

After completing required screening, eligible participants underwent posterior iliac crest bone marrow aspiration under local anesthetic to obtain 20–50 mL of marrow. Bilateral aspiration was performed when necessary. MSCs were isolated and culture-expanded

using established standardized procedures.⁴ At each passage after the primary culture, 1×10^6 cells were frozen for laboratory analysis. The cells were propagated in culture for up to 8 weeks in low-glucose Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum (FBS) prescreened for optimal MSC growth and 10 ng/mL human fibroblast growth factor-2 (R&D Systems, Minneapolis, MN). Conditioned culture medium was tested for microbiological contamination at each passage, and the culture terminated if microorganisms were detected. On the day of MSC harvest, the cells were detached from culture flasks using porcine trypsin and washed three times with PlasmaLyte plus 1% human serum albumin. Cell aliquots were evaluated for viability by trypan blue exclusion and cell surface phenotype by cytofluorometry with monoclonal antibodies for CD105, CD73, CD14, and CD45. An aliquot of the final cell product was tested for the presence of mycoplasma, and the conditioned medium was tested for aerobic and anaerobic bacteria, endotoxin, and fungus. MSCs were cryopreserved in a single Cryocyte freezing bag (plus two 1-mL satellite vials for quality assurance/quality control testing if needed), at final concentration of 4×10^6 /mL, in PlasmaLyte A containing 10% dimethyl sulfoxide and 5% human serum albumin.

Release criteria for the post-expansion/pre-cryopreservation MSC product included the following:

- Availability of at least 1×10^6 MSCs/kg participant body weight.
- $\geq 90\%$ positivity for CD105/CD73, and $< 5\%$ positivity for CD14/CD45 surface markers.
- Absence of detectable bacteria, fungus, mycoplasma, or endotoxin.

In addition, $\geq 70\%$ viability by trypan blue exclusion of an aliquot of the infusion product after thaw was required. If a culture was contaminated or provided inadequate cell yield, a second aspirate was requested from the participant.

After completion of the baseline (month 0) visit, participants received a single intravenous (IV) infusion of $1\text{--}2 \times 10^6$ /kg body weight MSCs without premedication. Vital signs, percutaneous oxygen saturation, electrocardiogram, and adverse events (AEs) were monitored for 6 hours following infusion.

Procedures

Safety assessments (AE monitoring, concomitant medication review, vital signs, weight, height, percutaneous

oxygen saturation by pulse oximetry, general physical examination, blood chemistry, complete blood count, and urinalysis) were performed at screening (median, -2.7 months); baseline (month 0); post-infusion days 1, 4, 7, 14, 21; and months 1, 2, 3, and 6. Clinical immunology studies (thyroid stimulating hormone, anti-thyroglobulin antibodies, anti-microsomal antibodies, sedimentation rate, C-reactive protein, anti-nuclear antibodies, SSA, SSB, rheumatoid factor, and lymphocyte subsets by cytofluorometry) were performed at; baseline; and months 1, 3, and 6. Chest X-ray and electrocardiogram were performed at screening, and months 1 and 6. Participant self-reported global well-being using a visual analog scale, neurological examination and calculation of EDSS, Multiple Sclerosis Functional Composite (MSFC), high and low-contrast letter acuity using Sloan charts (LCLA), MRI, VEP, and OCT were performed at screening; month -1; baseline; and months 1, 2, 3, and 6. MRI scans were acquired on a 3T Siemens Trio MRI scanner (Erlangen, Germany) according to a standardized protocol (see Supplementary Appendix) and analyzed by the MRI Analysis Center (Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH). OCT was performed using a Cirrus spectral domain OCT machine (Carl Zeiss Meditec, Dublin, CA).

Outcomes

The study's primary objective was to evaluate the feasibility of culturing MSCs, and infusion-related safety and tolerability of autologous MSC transplantation over 1 month in participants with relapsing forms of MS. Secondary objectives included evaluation of safety and tolerability over 6 months and effects on disease activity measured by the number of gadolinium-enhancing MRI lesions at 1 month. Safety measures included AEs, vital signs, oxygen saturation, blood laboratory studies, clinical immunology studies, urinalysis, chest X-ray, and electrocardiogram. AE severity was categorized based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Pre-specified exploratory efficacy measures included participant self-report of global well-being using a visual analog scale; MS disease status (relapses, EDSS, MSFC); vision (high-contrast visual acuity, LCLA); brain MRI (gadolinium-enhancing lesion number and volume, new/enlarged T2-hyperintense lesion number, T2-hyperintense and T1-hypointense lesion volumes, normalized whole brain volume (brain parenchymal fraction), gray matter fraction, whole brain diffusion tensor imaging (mean diffusivity, fractional anisotropy), whole brain magnetization transfer

ratio (MTR)); VEP (P100 latency); and OCT (retinal nerve fiber layer thickness, foveal thickness, macular volume).

MS relapse was defined as new, recurrent, or increased MS symptom(s); developing acutely (evolving over less than 3 months); with onset at least 30 days after the onset of a previous confirmed relapse; lasting at least 24 hours; with new objective neurological findings on the examination; and not associated with infection, fever, increased body temperature for another reason, or metabolic derangement. Confirmed relapses could be treated at the Treating Neurologist's discretion with IV methylprednisolone 1000 mg/day for 3–5 days without an oral taper.

Statistical methods

Clinically significant treatment-related AEs were expected to be infrequent ($\leq 5\%$ of participants), based on accumulating experience with MSC transplantation.¹⁰ The trial was conducted under a group sequential monitoring plan, with interim examinations of treatment-related AEs after every fourth participant was followed for 1 month after infusion. Early stopping was to be considered if three participants within the first eight, or four participants overall, experienced treatment-related AE CTCAE grade ≥ 3 or treatment-related serious AE at any point during follow-up. This procedure followed an O'Brien-Fleming stopping rule for a nominal $\alpha = 5\%$ one-sided test of the composite null hypothesis of a 5% or lower risk of such a treatment-associated AE against the alternative of a higher risk. This plan gives a $\leq 3.2\%$ chance of a false finding of harm when true risk is $< 5\%$, and 89%, 74%, 50%, and 22% power to detect true risks of 25%, 20%, 15%, and 10%, respectively.

Descriptive methods were chosen appropriate to each variable's scale (i.e. nominal, ordinal, interval, ratio). Exploratory objectives were to assess the effect of MSC transplantation on the longitudinal course of MS. To this purpose, we fit mixed linear statistical models with random subject effects and, wherever possible, a time series covariance structure, to numerous continuous MS outcome measures, and examined trends using restricted cubic splines and custom tests between specified inter-visit comparisons. Categorical data and nonparametric methods were used for outcomes for which such models were inappropriate. As this was an open-label pilot study without a parallel control arm, and not powered to reliably detect temporal trends due to efficacy, *p*-values were used to describe compatibility of the data with absence of

MSC activity, but not for formal hypothesis testing. For most outcomes, the primary exploratory *p*-value compared slopes or means within 3 months post-infusion with the 2–3 month pre-infusion period.

Results

Of 24 participants initially consented, one exhibited gadolinium allergy during the screening MRI and was




Figure 1. CONSORT diagram.
MSC: mesenchymal stem cell; AE: adverse event.

not enrolled. Another's culture failed due to slow growth and development of atypical cellular morphology, first noted at the first passage. The participant had no distinguishing past medical history, MS features, or previous or concomitant medications. The participant elected not to undergo a second bone marrow aspiration and discontinued the study. Two replacement participants were consented and enrolled (Figure 1). Demographic, clinical, and imaging characteristics for the 25 enrolled participants are summarized in Table 1. Among the infused participants, yields following the initial Percoll gradient centrifugation, final yields, and kinetics of growth varied considerably, with no apparent relation to participant demographics, MS disease characteristics, or current or prior treatment, and despite adherence to standard protocols for bone marrow harvest and cell culture. Nevertheless, the cell dose was within the target range for all infused participants and for 22 (92%) within 5.5% of $2 \times 10^6/\text{kg}$ (Table 2). All planned visits and assessments were completed except for one blood study for one participant.

There were no severe (CTCAE grade ≥ 3) or serious AEs related to study treatment. Table 3 lists AEs experienced by ≥ 2 participants from infusion through follow-up. One participant with SPMS died 8 months after completing the study. After study follow-up, this patient had progressive neurologic disability, with further worsening after intrathecal baclofen pump placement requiring two revisions, and died in hospice with severe spastic quadriplegia but no unusual infections or other medical condition.

Table 1. Characteristics of participants who underwent bone marrow aspiration and MSC culture (screening visit).

Characteristic	Participants (<i>n</i> = 25)
Age, years (mean (SD))	46.4 (5.2)
Sex	17 females/8 males
Disease course	11 RR/14 SP
Disease duration, years, mean (SD)	15.4 (9.0)
MS disease activity or worsening in the prior two years, <i>n</i> (%) ^a	MS relapse 16 (64.0), EDSS or FSS worsening 11 (44.0), MSFC component worsening 17 (68.0), brain MRI lesion activity 10 (40.0), cervical spine lesion activity 1 (4.0)
EDSS, median (range)	6.0 (3.0–6.5)
Current disease treatment, <i>n</i> (%)	interferon-beta 6 (24.0), glatiramer acetate 7 (28.0), no treatment 12 (48.0)
MRI with gadolinium-enhancing lesions, <i>n</i> (%)	6 (24.0)
T2-hyperintense lesion volume, mL (mean (SD))	21.5 (12.0)
Brain parenchymal fraction, mean (SD)	0.777 (0.039)
MSC: mesenchymal stem cell; EDSS: Expanded Disability Status Scale; FSS: functional system score; MSFC: Multiple Sclerosis Functional Composite; MRI: magnetic resonance imaging; MS: multiple sclerosis; RR: relapsing-remitting; SD: standard deviation; SP: secondary progressive.	
^a The total exceeds 100% because some participants qualified based on more than one criterion.	

Table 2. Cell culture kinetics and yield ($n = 24$).

Parameter	Mean \pm SD (range)
Initial yield following Percoll centrifugation of bone marrow aspirate, 10^8 cells	5.05 \pm 2.72 (1.52–11.27)
Final yield following cell expansion, 10^8 cells	2.74 \pm 1.29 (0.86–5.86)
Culture duration, days	30.0 \pm 11.3 (16–62)
Percent CD105 ⁺ /CD73 ⁺	97.0 \pm 2.1 (90.6–99.7)
Percent CD45 ⁺ /CD14 ⁺	0.36 \pm 0.46 (0.00–1.79)
Infused dose, 10^6 cells/kg	1.9 \pm 0.14 (1.5–2.0)
Viability: trypan blue exclusion of administered cells	98.6 \pm 0.9 (95.2–99.5)
SD: standard deviation. There was one culture failure that was terminated after 28 days due to poor growth and atypical cell morphology.	

Table 3. Adverse events during or after autologous MSC infusion among participants who underwent infusion ($n = 24$).

Events	Number (%) of participants
Any event	22 (92)
Any severe event ^a	3 (12.5) ^c
Any event leading to discontinuation of trial participation	0
Any serious event	4 (16.7) ^c
Deaths	0 ^d
<i>Most frequently reported events^b</i>	
Muscle spasticity	11 (45.8)
Urinary tract infection	10 (41.7)
Multiple sclerosis relapse	7 (29.2)
Fall	7 (29.2)
Multiple sclerosis	5 (20.8)
Vision blurred	5 (20.8)
Upper respiratory tract infection	5 (20.8)
Balance disorder	4 (16.7)
Nasopharyngitis	3 (12.5)
Depression	3 (12.5)
Diarrhea	3 (12.5)
Blood thyroid stimulating hormone decreased	2 (8.3)
Back pain	2 (8.3)
Fatigue	2 (8.3)
Paresthesia	2 (8.3)
Anxiety	2 (8.3)
Migraine	2 (8.3)
Headache	2 (8.3)
MSC: mesenchymal stem cell; CTCAE: Common Terminology Criteria for Adverse Events. ^a CTCAE grade ≥ 3 . ^b Reported by ≥ 2 participants. ^c Events classified as both severe and serious included: hospitalizations of two participants for treatment of a urinary tract infection with associated temporary worsening of neurologic symptoms, two hospitalizations of one participant for depression, hospitalization of one participant for management of hyperglycemia following IV methylprednisolone treatment of an MS relapse. None were considered related to mesenchymal stem cell transplantation. ^d Two deaths occurred, 6 months and 40 months after completing the study, not considered related to mesenchymal stem cell transplantation.	

A second participant with SPMS died 40 months after completing the study after choking on food. We are unaware of other participants with unexpected AEs after study completion.

No participant developed clinical manifestations or serologic studies indicating autoimmune phenomena. There was no clinical or radiographic evidence of paradoxical MS disease activation (Table 4). Although an active MRI was not required at enrollment, 24–50% of MRIs at the three pre-infusion time points demonstrated gadolinium-enhancing lesions. Post-infusion, there was no evidence of activation or inhibition of gadolinium enhancement or new/enlarged T2-hyperintense MRI lesion accumulation. Among 24 infused participants, 18 (75%) were free of relapse, 3 (12.5%) experienced a single relapse during post-infusion follow-up, and 3 (12.5%) experienced two relapses (two pre-infusion, four post-infusion). All relapses but one occurred in participants with RRMS. The single relapse in a participant with SPMS (but with a gadolinium-enhancing lesion at screening) was documented at the final visit. Among participants with RRMS, annualized relapse rates were 0.81 (95% CI: 0.10–2.93) pre-infusion, 1.85 (95% CI 0.50–4.73) in months 1–3 post-infusion, and 0.90 (95% CI: 0.11–3.24) in months 4–6 post-infusion ($p = 0.58$).

Most other exploratory efficacy outcomes were generally stable over the course of the study (Table 4). Descriptive p -values fell below the conventional 5% for three outcomes, compatible with two expected by chance alone based on the number of outcomes studied. These outcomes were whole brain MTR ($p = 0.03$) and MTR peak height ($p = 0.008$), both of which trended upward in post-infusion months 1–3 relative to pre-infusion, and EDSS (signed rank $p = 0.001$), for which three post-infusion measurements worsened while 17 were improved from baseline, with others stable. Improvement in the EDSS reflected improvements in ambulation, and cerebral and sensory subsystems.

Discussion

Previous experience in other disorders and limited published experience in MS suggested MSC transplantation would be safe and well tolerated. However, unanticipated autoimmune AEs have occurred with other MS therapies, for example, alemtuzumab,¹¹ altered peptide ligands,¹² and tumor necrosis factor blockade.¹³ Therefore, based on regulatory input on study design, we conducted a pilot study focusing on feasibility, safety, and tolerability. During our study's start-up preparations, the MSCT Study Group recommended a phase 2 design,¹⁴ stimulating the multinational Mesenchymal Stem Cells for Multiple Sclerosis (MESEMS) trial from which preliminary results recently were reported by a participating center.³

Our phase I study results support the feasibility, safety, and tolerability of IV administration of autologous, culture-expanded, bone-marrow-derived MSCs in MS. No treatment-related severe or serious AEs occurred during the follow-up period. The deaths of two participants after completing the trial did not appear to be related to MSC transplantation. Since the study was relatively small with only 6-month follow-up, we cannot rule out the possibility of rare or late-appearing AEs.

Exploratory efficacy measures demonstrated no substantial evidence of inhibition of disease activity, tissue repair, or recovery of function comparing 2–3 months pre-infusion to 6 months post-infusion. Given the lack of comparison group, small sample size, and relatively short follow-up, demonstration of benefit was not anticipated. There was a suggestion of possible benefit on EDSS. This result must be interpreted most cautiously, particularly without evidence of benefit on other disability measures. In the 4.0–5.5 range, where improvement was seen, the EDSS score is determined primarily by distance a participant walks. A participant's motivation and degree of examiner encouragement can be affected by expectation effects, as can the cerebral and sensory system scores that also improved. The benefit on two MTR measures could be random false positives among the dozens of outcome variables examined.

Lack of inhibition of gadolinium-enhancing lesions was surprising given the pleiotropic anti-inflammatory actions of MSCs. One possibility is MSCs lack MS-relevant anti-inflammatory activity in vivo despite suggestive data from in vitro and animal studies. Or, possibly, the cell dose was insufficient. There were few data to guide dose selection when this study was designed. The target dose, 2×10^6 MSCs/kg body weight, was based on a dose effective in treating graft-versus-host disease following allogeneic hematopoietic stem cell transplantation¹⁵ and was anticipated to be safe and reliably achievable based on our experience with MSC transplantation for several conditions.¹⁶ Also, multiple administrations might be more effective.¹⁷ Third, there is no current consensus concerning optimal delivery route. We elected to administer cells IV because of ease of administration and data supporting ability of MSCs to traffic from blood to injured or inflamed central nervous system in animal models of stroke, brain tumor, traumatic brain injury, spinal cord demyelination, and MS.¹ This route has been employed in most studies of MSC transplantation in MS.¹ Although the lungs trap many cells following IV injection, numerous cells reach systemic circulation and become widely distributed in experimental models and

Table 4. Exploratory efficacy results ($n = 24$ for all values unless otherwise specified).

	Screening	Month -1	Baseline	Month 1	Month 2	Month 3	Month 6
Participant self-reported outcome							
Global well-being by visual analog scale, mm from the left							
Mean \pm SD	73.2 \pm 17.2	NA	66.6 \pm 15.9	67.9 \pm 15.0	67.8 \pm 16.0	58.6 \pm 21.8	68.2 \pm 17.0
Clinician-assessed outcomes							
Expanded Disability Status Scale							
Mean \pm SD	5.2 \pm 1.4	5.3 \pm 1.4	5.3 \pm 1.3	5.1 \pm 1.5	4.9 \pm 1.8	5.1 \pm 1.7	5.0 \pm 1.7
Median (range)	6.0 (3.0–6.5)	6.0 (3.0–6.5)	6.0 (3.0–6.5)	6.0 (2.0–6.5)	6.0 (1.5–6.5)	6.0 (2.0–6.5)	6.0 (2.0–6.5)
Multiple Sclerosis Functional Composite^{4b}							
Mean \pm SD	-0.17 \pm 0.60	-0.13 \pm 0.62	-0.14 \pm 0.61	-0.09 \pm 0.57	-0.07 \pm 0.57	-0.12 \pm 0.56	-0.13 \pm 0.58
Timed 25-foot walk, seconds							
Mean \pm SD	9.8 \pm 4.9	10.2 \pm 5.5	10.1 \pm 5.0	9.8 \pm 4.9	10.2 \pm 5.0	11.6 \pm 6.8	11.4 \pm 6.9
9-hole peg test, seconds							
Right, mean \pm SD	28.4 \pm 11.6	28.5 \pm 12.0	30.3 \pm 21.1	29.7 \pm 15.9	28.8 \pm 17.4	28.1 \pm 14.7	27.8 \pm 14.1
Left, mean \pm SD	27.8 \pm 9.7	28.8 \pm 11.7	28.3 \pm 9.6	27.9 \pm 9.7	27.6 \pm 8.8	26.9 \pm 8.7	27.9 \pm 9.7
Paced auditory serial addition test, n correct							
Mean \pm SD	45.3 \pm 11.4	49.0 \pm 10.0	47.9 \pm 10.2	49.5 \pm 10.3	49.8 \pm 9.2	51.1 \pm 8.6	50.8 \pm 8.8
Sloan low-contrast letter acuity, binocular, n correct							
100%, mean \pm SD	56.6 \pm 4.6	56.3 \pm 4.1	56.4 \pm 5.2	56.7 \pm 4.6	55.9 \pm 5.5	55.7 \pm 5.7	56.3 \pm 5.2
2.5%, mean \pm SD	32.5 \pm 9.6	31.3 \pm 8.3	31.3 \pm 9.7	31.1 \pm 9.2	29.0 \pm 9.2	30.7 \pm 8.7	30.8 \pm 9.4
1.25%, mean \pm SD	17.0 \pm 12.5	15.5 \pm 11.6	16.5 \pm 12.1	16.6 \pm 11.4	16.5 \pm 9.8	14.0 \pm 9.0	13.9 \pm 9.4
MRI outcomes							
Gadolinium-enhancing lesions, n							
Mean \pm SD	0.58 \pm 1.53	0.63 \pm 1.20	0.75 \pm 0.90	0.96 \pm 1.57	0.92 \pm 1.89	0.67 \pm 1.37	0.79 \pm 1.41
Median (range)	0 (0–7)	0 (0–5)	0.5 (0–3)	0 (0–6)	0 (0–6)	0 (0–5)	0 (0–5)
Proportion of scans with gadolinium-enhancing lesions							
n (%)	6 (25)	8 (33)	12 (50)	9 (38)	8 (33)	7 (29)	8 (33)
Number of new or enlarged T2-hyperintense lesions (compared to the screening MRI), n							
Mean \pm SD	NA	0.63 \pm 0.92	0.92 \pm 1.25	1.29 \pm 1.78	1.38 \pm 1.81	1.54 \pm 2.23	1.79 \pm 2.48
Median (range)	NA	0 (0–3)	0.5 (0–3)	0 (0–6)	0 (0–6)	0 (0–8)	0 (1–10)
T2-hyperintense lesion volume, mL							
Mean \pm SD	21.6 \pm 12.2	21.8 \pm 12.5	22.2 \pm 13.0	22.5 \pm 13.0	22.1 \pm 13.0	22.2 \pm 13.0	22.0 \pm 12.8

(Continued)

Table 4. (Continued)

	Screening	Month -1	Baseline	Month 1	Month 2	Month 3	Month 6
T1-hypointense lesion volume, mL							
Mean ± SD	3.44 ± 3.20	3.36 ± 3.11	3.41 ± 3.13	3.36 ± 3.10	3.32 ± 3.00	3.32 ± 3.02	3.31 ± 2.98
Normalized brain volume (brain parenchymal fraction)							
Mean ± SD	0.776 ± 0.039	0.775 ± 0.040	0.775 ± 0.039	0.774 ± 0.039	0.773 ± 0.040	0.774 ± 0.040	0.772 ± 0.041
Gray matter fraction							
Mean ± SD	0.460 ± 0.020	0.460 ± 0.020	0.460 ± 0.020	0.459 ± 0.020	0.459 ± 0.021	0.457 ± 0.021	0.458 ± 0.021
Whole brain mean diffusivity, $\times 10^{-6}$ mm ² /s							
Mean ± SD	836.7 ± 33.8	841.1 ± 33.0 ^a	840.9 ± 29.7	845.1 ± 32.6 ^a	844.3 ± 33.3	843.9 ± 35.3 ^a	845.4 ± 33.4
Whole brain fractional anisotropy							
Mean ± SD	282.8 ± 11.3	282.5 ± 10.4 ^a	281.5 ± 10.4	281.8 ± 10.6 ^a	279.9 ± 11.7	282.2 ± 11.9 ^a	282.0 ± 10.5
Whole brain magnetization transfer ratio							
Mean ± SD	37.51 ± 2.56	37.49 ± 2.60	37.44 ± 2.66	37.50 ± 2.61	37.52 ± 2.62	37.62 ± 2.58	37.64 ± 2.59
Visual evoked potentials							
P100 latency, average of both eyes, milliseconds							
Mean ± SD	133.3 ± 17.3	135.5 ± 19.1	133.1 ± 19.8	135.0 ± 19.2	135.3 ± 18.3	135.9 ± 18.5	137.1 ± 18.8
Optical coherence tomography							
Retinal nerve fiber layer thickness, average of both eyes, μ m							
Mean ± SD	72.7 ± 7.6	72.8 ± 7.6	72.9 ± 8.2	72.6 ± 7.8	72.0 ± 7.7	72.3 ± 7.8	72.2 ± 7.7
Macular volume, average of both eyes, μ m ³							
Mean ± SD	9.38 ± 0.46	9.36 ± 0.47	9.34 ± 0.50	9.34 ± 0.47	9.35 ± 0.44	9.35 ± 0.45	9.31 ± 0.51
Foveal thickness, average of both eyes, μ m							
Mean ± SD	261.78 ± 12.86	261.20 ± 12.58	260.68 ± 13.95	260.50 ± 12.96	260.89 ± 12.26	261.01 ± 12.50	259.72 ± 14.14

SD: standard deviation; MRI: magnetic resonance imaging; NA: not available, because not measured at that visit.

^a*n* = 23.^bTimed 25-foot walk, 9-hole peg test, paced auditory serial addition test, low-contrast letter acuity.

human studies.¹⁸ Intra-carotid delivery of MSCs, which has been explored in multiple system atrophy¹⁹ but not in MS to date, raises microembolization concerns. Some studies have utilized an intrathecal, or combined IV and intrathecal routes.^{20–22} Finally, we utilized cryopreserved cells thawed just before infusion. Although viability of the infused cell product exceeded 95% in all cases, recent studies suggest that, immediately after thawing, cryopreserved MSCs have cytoskeletal changes,²³ impaired immunomodulatory function,^{24,25} altered *in vivo* trafficking,²⁶ and increased T-cell-mediated apoptosis.²³ Thus, harvesting cells directly from culture or allowing recovery time after thawing appears prudent.

Another cell production issue in designing the planned phase 2 study is use of FBS in our culture protocol. Although we received regulatory approval based on our previous experience, validation of a xeno-free culture protocol for future studies is underway. Preliminarily, MSCs from five normal donors have been culture-expanded in parallel in low-glucose DMEM containing 10% FBS or 5% human platelet lysate (PLUS supplement). Mean yields after three passages were more than tripled and culture times nearly halved with platelet lysate, with equivalent purity.²⁷

We utilized bone-marrow-derived MSCs based on our previous experience, but important differences might exist between MSCs from different tissue sources, for example, adipose tissue and bone marrow, a point not yet systematically investigated. A related issue is whether MSCs should be autologous or can/should be isolated from donors without MS. We used autologous cells to avoid potential concerns with transmitting infection or cancer from the donor. Also, although MSCs are relatively non-immunogenic permitting allogeneic administration,^{15,28} some studies indicate repeated administration stimulates rejection²⁹—an issue if multi-dosing is planned. Conversely, “universal donor” MSCs have the advantage of an “off the shelf” reagent with consistent properties and would not be subject to putative deficient immunomodulatory or repair-promoting properties associated with MS. While some studies indicate that MSCs isolated from MS subjects and non-MS controls exhibit similar growth in culture, differentiation potential, surface antigen expression, and immunomodulatory properties,^{30–32} others report notable functional differences,^{33–35} suggesting administration of MSCs from a donor without MS might be preferable. This key issue is unresolved and is the subject of ongoing ancillary studies.

In summary, this phase 1 trial supports the feasibility, safety, and tolerability of autologous MSC transplantation

in MS. Future trials to assess efficacy more definitively are warranted.

Acknowledgements

The authors thank Cynthia Mackey, RN, BSN, MSN; Vinette Zinkand, RN; Robert Fox, RN; the staff of the Dahms Clinical Research Unit, Seidman Cancer Center; the Advisory Committee (Supplementary Appendix); and the Data Safety Monitoring Committee (Supplementary Appendix) for their assistance with the study. Preliminary results of this study were presented at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, MA, USA, 10–13 September 2014. J.A.C., P.B.I., S.M.P., E.F., A.B.-O., J.R.K., S.L.G., and H.M.L. contributed to study conception or design. All authors contributed to study supervision or coordination and analysis or interpretation of data. P.B.I., M.K., and S.M. contributed to statistical analysis. All authors contributed to drafting and revising the manuscript for content. Clinicaltrials.gov identifier: NCT00813969.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J.A.C. reports consulting fees from Adamas, Merck, Mallinckrodt, Novartis, and Receptos and compensation as Co-Editor of *Multiple Sclerosis Journal: Experimental, Translational and Clinical*. R.A.B. reports consulting fees from Biogen, Genentech, Genzyme, and Novartis. E.F. is an employee of Biogen. R.J.F. reports consulting fees from Actelion, Biogen, Genentech, Mallinckrodt, MedDay, Novartis, and Teva and research funding from Novartis. A.B.-O. reports consulting fees from Biogen Merck, Novartis, Receptos, Roche, Sanofi-Genzyme, and Teva. P.B.I., S.M.P., S.L.S., T.T.S., P.J., M.K., S.M., J.R.K., S.L.G., and H.M.L. have nothing to disclose.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This trial was funded by Department of Defense Grant W81XWH-10-1-0270 and National Institutes of Health Grant RO1 NS074787, National Multiple Sclerosis Society Pilot Grant PP-1752, and Cleveland Clinic RPC Grant 2012-2017. The Dahms Clinical Research Unit is funded by the Clinical and Translational Science Collaborative of Cleveland UL1000439 from the National Center for Advancing Translational Sciences component of the National Institutes of Health and NIH Roadmap for Medical Research. The contents of the manuscript are solely the responsibility of the

authors and do not necessarily represent the official views of the NIH.

References

1. Cohen JA. Mesenchymal stem cell transplantation in multiple sclerosis. *J Neurol Sci* 2013; 333: 43–49.
2. Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. *Lancet Neurol* 2012; 11: 150–156.
3. Llufrui S, Sepulveda M, Blanco Y, et al. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. *PLoS ONE* 2014; 9: e113936.
4. Lazarus HM, Haynesworth SE, Gerson SL, et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): Implications for therapeutic use. *Bone Marrow Transplant* 1995; 16: 557–564.
5. ICH harmonised tripartite guideline: Guideline for good clinical practice—E6(R1). International conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, 10 June 1996, http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (accessed 28 September 2014).
6. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects, <http://www.wma.net/en/30publications/10policies/b3/index.html> (accessed 22 August 2016).
7. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria. *Ann Neurol* 2011; 69: 292–302.
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). *Neurology* 1983; 33: 1444–1452.
9. Swanton JK, Rovira A, Tintore M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: A multicentre retrospective study. *Lancet Neurol* 2007; 6: 677–686.
10. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials. *PLoS ONE* 2012; 7: e47559.
11. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. *Lancet* 1995; 354: 1691–1695.
12. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. *Nat Med* 2000; 6: 1167–1175.
13. The Lenercept Multiple Sclerosis Study Group; The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. *Neurology* 1999; 53: 457–465.
14. Freedman MS, Bar-Or A, Atkins HL, et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: Consensus report of the International MSCT Study Group. *Mult Scler* 2010; 16: 503–510.
15. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. *Lancet* 2008; 371: 1579–1586.
16. Koc ON, Day J, Nieder M, et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). *Bone Marrow Transplant* 2002; 30: 215–222.
17. Harris VK, Yan QJ, Vyshkina T, et al. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. *J Neurol Sci* 2012; 313: 167–177.
18. Cogle CR, Yachnis AT, Laywell ED, et al. Bone marrow transdifferentiation in brain after transplantation: A retrospective study. *Lancet* 2004; 363: 1432–1437.
19. Lee PH, Lee JE, Kim H-S, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. *Ann Neurol* 2012; 72: 32–40.
20. Karussis D, Karageorgiou C, Vakhnin-Dembinsky A, et al. Safety and immunologic effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. *Arch Neurol* 2010; 67: 1187–1194.
21. Moyeddin Bonab M, Yazdanbakhsh S, Loft J, et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? *Iran J Immunol* 2007; 4: 50–57.
22. Yamout B, Hourani R, Salti H, et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study. *J Neuroimmunol* 2010; 227: 185–189.
23. Chinnadurai R, Copland IB, Garcia MA, et al. Cryopreserved mesenchymal stromal cells are susceptible to T-cell mediated apoptosis which is partly rescued by IFN γ licensing. *Stem Cells* 2016; 34: 2429–2442.

24. Francois M, Copland IB, Yuan S, et al. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon- γ licensing. *Cytherapy* 2012; 14: 147–152.
25. Moll G, Alm JJ, Davies LC, et al. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? *Stem Cells* 2014; 32: 2430–2442.
26. Chinnadurai R, Garcia MA, Sakurai Y, et al. Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo. *Stem Cell Reports* 2014; 3: 60–72.
27. Reese JS, Hooper BM, Lazarus HM, et al. Identification of an alternative to fetal bovine serum for the culture expansion of human mesenchymal stem cells for use in clinical studies (P901). *Mult Scler J* 2014; 20(Suppl. 1): 461.
28. Rasmusson I, Uhlin M, Le Blanc K, et al. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. *J Leukoc Biol* 2007; 82: 887–893.
29. Eliopoulos N, Stagg J, Lejeune L, et al. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. *Blood* 2005; 106: 4057–4065.
30. Papadaki HA, Tsagournisakis M, Mastorodemos V, et al. Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis. *Bone Marrow Transplant* 2005; 36: 1053–1063.
31. Mazzanti B, Aldinucci A, Biagioli T, et al. Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implications for assessment of disease activity and treatment. *J Neuroimmunol* 2008; 199: 142–150.
32. Mallam E, Kemp K, Wilkins A, et al. Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. *Mult Scler* 2010; 16: 909–918.
33. De Oliveira GLV, de Lima KWA, Colombini AM, et al. Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts. *Cell Transplant* 2015; 24: 151–165.
34. Sarkar P, Redondo J, Kemp K, et al. Reduced expression of mitochondrial fumarate hydratase contributes to impaired MSC-mediated neuroprotection in multiple sclerosis. *Mult Scler J* 2016; 22(S3): 38–39.
35. Redondo J, Sarkar P, Kemp K, et al. Alterations in the secretome of MSCs isolated from patients with MS are in keeping with their reduced neuroprotective potential under conditions of oxidative stress. *Mult Scler J* 2016; 22(S3): 321.

Visit SAGE journals online
journals.sagepub.com/
home/msj

 SAGE journals